MAIA Biotechnology Hits Key Enrollment Goals in Lung Cancer Trials
MAIA Biotechnology has completed enrollment in a Phase 2 trial segment and reached 65% of its Phase 3 target for non-small cell lung cancer studies.
MAIA Biotechnology has announced two significant enrollment milestones in its ongoing clinical trials targeting non-small cell lung cancer, signaling continued momentum in the company's drug development pipeline.
The Chicago-based biotech firm confirmed that enrollment in Part C of its THIO-101 Phase 2 study is now complete, a benchmark that allows researchers to move forward with data collection and analysis for that cohort. Completing enrollment in a Phase 2 segment is a prerequisite for generating the evidence needed to support late-stage trial design.
Read more BillionToOne ctDNA Test Matches Tumor-Informed Assay in New Study →
In its larger pivotal THIO-104 Phase 3 study, MAIA reported reaching 65% of its full enrollment target for 2026. Pivotal Phase 3 trials carry particular regulatory weight, as successful results can form the basis of a new drug application submitted to the FDA. Sustained enrollment progress in such studies is closely watched by investors and oncology researchers alike.
Non-small cell lung cancer represents the most common form of lung cancer, accounting for the vast majority of diagnoses in the United States each year. The disease remains a leading cause of cancer-related mortality, and new therapeutic approaches that can demonstrate efficacy in late-stage trials are in significant demand within the oncology community.
The dual milestones underscore MAIA's stated commitment to advancing its THIO-based telomere-targeting platform through the clinical development process. Continue reading at GlobeNewswire - Industry News on Financial Services.
